TEVA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

32.380

Open

32.380

VWAP

31.55

Vol

12.24M

Mkt Cap

36.66B

Low

30.800

Amount

386.26M

EV/EBITDA(TTM)

9.71

Total Shares

1.16B

EV

50.21B

EV/OCF(TTM)

29.29

P/S(TTM)

2.14

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Show More

Events Timeline

(ET)

2026-06-18

17:30:00

Teva Pharmaceuticals Submits NDA for Tourette Syndrome Drug to FDA

2026-06-05 (ET)

2026-06-05

11:40:00

Teva Releases New Data on Huntington's Disease, AUSTEDO Improves Quality of Life

2026-06-04 (ET)

2026-06-04

09:00:00

Teva Launches Biosimilar Ahzantive in Europe

2026-06-04

05:20:00

Alvotech Resubmits Biologics License Applications for AVT05 and AVT06 to FDA

2026-05-27 (ET)

2026-05-27

07:10:00

Teva Pharmaceuticals Commits to Veeva Vault CRM Globally

2026-05-21 (ET)

2026-05-21

12:40:00

Teva Pharmaceuticals Submits Long-Acting Olanzapine Application

News

Newsfilter

06-18Newsfilter

PinnedTeva Pharmaceuticals to Release Q2 2026 Financial Results

Fool

Teva Pharmaceuticals Transitions to Innovative Drug Development

NASDAQ.COM

06-19NASDAQ.COM

Teva Pharmaceuticals Reports Strong Q1 Performance

seekingalpha

06-18seekingalpha

Teva Seeks FDA Approval for Ecopipam in Pediatric Tourette Syndrome

Newsfilter

06-18Newsfilter

Teva Pharmaceuticals Releases Q2 2026 Aide Memoire

Newsfilter

06-18Newsfilter

Teva Submits NDA for Ecopipam to Treat Pediatric Tourette Syndrome

11 Analyst Rating

Wall Street analysts forecast TEVA stock price to rise

10 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

29.00

Averages

35.71

High

40.00

Current: 0.000

Low

29.00

Averages

35.71

High

40.00

Jefferies

Dennis Ding

Buy

maintain

$40

AI Analysis

2026-06-18

New

Reason

Jefferies

Dennis Ding

Price Target

$40

AI Analysis

2026-06-18

New

maintain

Buy

Reason

Noting that Teva has underperformed the last two weeks, Jefferies analyst Dennis Ding explained that a "big part of the weakness is due to macro," but also says it may potentially be due to how investors perceived management comments on vitiligo at a recent conference as well as a clinicaltrials.gov update showing vitiligo's primary completion is now September instead of May. However, after having caught up with the investor relations team, who noted there's no change to internal confidence on vitiligo and reiterated the data will be right after July 4 weekend, the firm continues to like shares after the pullback and keeps a Buy rating and $40 price target on Teva.

Barclays

NULL

to

Overweight

maintain

$38 -> $40

2026-05-06

Reason

Barclays

Price Target

$38 -> $40

2026-05-06

maintain

NULL

to

Overweight

Reason

Barclays raised the firm's price target on Teva to $40 from $38 and keeps an Overweight rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TEVA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Teva Pharmaceutical Industries Limited.. (TEVA.N) is 15.17, compared to its 5-year average forward P/E of 5.32. For a more detailed relative valuation and DCF analysis to assess Teva Pharmaceutical Industries Limited..'s fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

5.32

Current PE

15.17

Overvalued PE

7.89

Undervalued PE

2.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

7.55

Current EV/EBITDA

11.57

Overvalued EV/EBITDA

9.82

Undervalued EV/EBITDA

5.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

1.02

Current PS

2.12

Overvalued PS

1.51

Undervalued PS

0.52

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

xene swing trade

Intellectia · 61 candidates

Sector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, PharmaceuticalsRsi Category: moderateRelative Vol: >= 1.20List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA60Is Optionable: TrueSupport Resistance Relationship: PriceBreakResistance, PriceAroundResistance

Ticker

Name

Market Cap$

ArriVent BioPharma Inc

1.41B

Scilex Holding Co

75.57M

MeiraGTx Holdings PLC

986.29M

Teva Pharmaceutical Industries Limited..

41.13B

Gilead Sciences, Inc

166.90B

Revolution Medicines Inc

33.48B

si quiero con acciones de estados unidos

Intellectia · 30 candidates

Market Cap: >= 10.00BRegion: USPrice: $10.00 - $60.00Analyst Consensus: Strong BuyPe Ttm: 5 - 30List Exchange: XNYS, XNAS

Ticker

Name

Market Cap$

Bank of America Corp

384.66B

SLB NV

78.36B

Nu Holdings Ltd.

73.40B

Barrick Mining Corp

71.97B

Manulife Financial Corp

64.64B

Baker Hughes Co

58.68B

top 10 crypto gainers today

Intellectia · 512 candidates

Price Change Pct 24h: >= $0.00

Ticker

Name

Market Cap$

Zeta

6.11M

Measurable Data Token

5.68M

AKEDO

9.28M

Kindred Labs

1.88M

Unite

106.81K

Just a chill guy

11.99M

no which two coins under .01

Intellectia · 347 candidates

Turnover 24h: >= 0Price: $0.00 - $0.01Relative Vol: >= 0Dollar Volume 24h: >= 0

Ticker

Name

Market Cap$

Pepe

1.65B

Gravity

56.10M

Pump.fun

716.00M

Bonk

579.97M

Pudgy Penguins

498.58M

Shiba Inu

3.66B

What stoke should I buy ?

Intellectia · 60 candidates

Market Cap: >= 30.00BQuarter Revenue Yoy Growth: >= 10.0%Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA200Monthly Average Dollar Volume: >= 1,500,000

Ticker

Name

Market Cap$

Lumentum Holdings Inc

42.87B

Western Digital Corp

96.32B

Micron Technology Inc

449.96B

Comfort Systems USA Inc

47.19B

Anglogold Ashanti PLC

53.60B

Kinross Gold Corp

40.90B

stocks to buy tomorrow

Intellectia · 358 candidates

Market Cap: >= 5.00BRegion: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 55Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

Teradyne Inc

43.25B

HF Sinclair Corp

10.32B

ArcelorMittal SA

44.06B

Archrock Inc

5.35B

Exact Sciences Corp

19.49B

American Electric Power Company Inc

64.75B

show me large cap stocks with key reversal

Intellectia · 44 candidates

Market Cap: >= 10.00BNew High Low: 52w_High, 52w_Low, 20_High, 20_LowCandlestick Pattern: UpperShadow, LowerShadow

Ticker

Name

Market Cap$

Walmart Inc

949.57B

Cisco Systems Inc

309.45B

AstraZeneca PLC

287.64B

Merck & Co Inc

273.69B

Texas Instruments Inc

193.96B

Mizuho Financial Group Inc

106.59B

stocks currently in bullish trend

Intellectia · 39 candidates

Market Cap: >= 10.00BList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Quarter Price Change Pct: >= $50.00Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

Micron Technology Inc

439.39B

Newmont Corporation

140.53B

Carvana Co

104.69B

Freeport-McMoRan Inc

89.29B

Barrick Mining Corp

86.76B

Western Digital Corp

86.45B

give me your top pick

Intellectia · 10 candidates

Market Cap: >= 10.00BMarket Cap Category: mega, largeAnalyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Month Predict Return: >= 15.0%

Ticker

Name

Market Cap$

Ross Stores Inc

60.49B

NiSource Inc

20.77B

APi Group Corp

18.28B

Meta Platforms Inc

1.63T

EMCOR Group Inc

31.47B

Penumbra Inc

14.07B

Whales Holding TEVA

Polar Capital Holdings Plc

Castle Hook Partners LP

Hennion & Walsh Asset Management, Inc.

Harel Insurance Investments & Financial Services Ltd

WCM Investment Management

Menora Mivtachim Provident Funds

Trading Trends

People Also Watch

Frequently Asked Questions

What is Teva Pharmaceutical Industries Limited.. (TEVA) stock price today?

The current price of TEVA is 31.48 USD — it has decreased -3.32

What is Teva Pharmaceutical Industries Limited.. (TEVA)'s business?

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

What is the price predicton of TEVA Stock?

Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is35.71 USD with a low forecast of 29.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Teva Pharmaceutical Industries Limited.. (TEVA)'s revenue for the last quarter?

Teva Pharmaceutical Industries Limited.. revenue for the last quarter amounts to 3.97B USD, increased 1.33

What is Teva Pharmaceutical Industries Limited.. (TEVA)'s earnings per share (EPS) for the last quarter?

Teva Pharmaceutical Industries Limited... EPS for the last quarter amounts to 0.31 USD, increased 63.16

How many employees does Teva Pharmaceutical Industries Limited.. (TEVA). have?

Teva Pharmaceutical Industries Limited.. (TEVA) has 31173 emplpoyees as of June 20 2026.

What is Teva Pharmaceutical Industries Limited.. (TEVA) market cap?

Today TEVA has the market capitalization of 36.66B USD.